Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Interest Coverage 2.71
AKRX's Interest Coverage is ranked lower than
99.99% of the 458 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 24.68 vs. AKRX: 2.71 )
Ranked among companies with meaningful Interest Coverage only.
AKRX' s Interest Coverage Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 0
Current: 2.71
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
» AKRX's 10-Y Financials

Financials (Next Earnings Date: 0)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2015

AKRX Guru Trades in Q2 2015

Steven Cohen 485,000 sh (+147.20%)
Mario Gabelli 23,100 sh (+77.69%)
Paul Tudor Jones 32,050 sh (+14.56%)
Murray Stahl 19,285 sh (+8.83%)
George Soros Sold Out
Joel Greenblatt Sold Out
Columbia Wanger 3,422,713 sh (-18.69%)
Louis Moore Bacon 7,400 sh (-89.43%)
» More
Q3 2015

AKRX Guru Trades in Q3 2015

Jim Simons 274,120 sh (New)
Mario Gabelli 29,500 sh (+27.71%)
Louis Moore Bacon Sold Out
Paul Tudor Jones Sold Out
Murray Stahl 18,866 sh (-2.17%)
Columbia Wanger 3,316,265 sh (-3.11%)
Steven Cohen 374,100 sh (-22.87%)
» More
Q4 2015

AKRX Guru Trades in Q4 2015

John Paulson 2,879,138 sh (New)
George Soros 20,100 sh (New)
Andreas Halvorsen 1,841,346 sh (New)
Steven Cohen 427,865 sh (+14.37%)
Mario Gabelli 31,100 sh (+5.42%)
Jim Simons Sold Out
Murray Stahl 16,548 sh (-12.29%)
Columbia Wanger 2,735,646 sh (-17.51%)
» More
Q1 2016

AKRX Guru Trades in Q1 2016

Murray Stahl 27,192 sh (+64.32%)
» More
» Details

Insider Trades

Latest Guru Trades with AKRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Akorn Inc

John Paulson Increases Bet on Health Care for 7th Quarter Hedge fund manager increased sector for seventh consecutive quarter to more than half of long portfolio
As 13F filings rolled in this week, the most notable revelation of John Paulson (Trades, Portfolio)’s was his reduction of his SPDR Gold Trust (GLD) stake, a mainstay of his portfolio for years, at a significant loss. Paulson, the head of hedge fund Paulson & Co., in his next most prominent move increased his holding of health care stocks for the seventh consecutive quarter. The sector made up more than 57% of his long portfolio, compared to 48.3% the previous quarter. Read more...

Ratios

vs
industry
vs
history
Forward P/E 10.43
AKRX's Forward P/E is ranked lower than
99.99% of the 69 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.85 vs. AKRX: 10.43 )
Ranked among companies with meaningful Forward P/E only.
N/A

Valuation & Return

vs
industry
vs
history

More Statistics

Revenue(Mil) $593
EPS $ 0.24
Beta1.75
Short Percentage of Float14.13%
52-Week Range $17.57 - 48.53
Shares Outstanding(Mil)114.43

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 980 1,085 1,183 1,288
EPS($) 1.90 2.16 2.44 2.74
EPS without NRI($) 1.90 2.16 2.44 2.74

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:SHSE:600521, SZSE:000999, HKSE:00867, NAS:HZNP, NYSE:CTLT » details
Traded in other countries:FDA.Germany,
Akorn Inc is a Louisiana corporation founded in 1971 in Abita Springs, Louisiana. The Company manufactures and markets a full line of diagnostic and therapeutic ophthalmic pharmaceuticals as well as niche hospital drugs and injectable pharmaceuticals. In addition, it has markets and distributes vaccines purchased from outside sources. It operates pharmaceutical manufacturing facilities in Decatur, Illinois and Somerset, New Jersey, and in Paonta Sahib, Himachal Pradesh, India. It also operates a Research and Development center in Vernon Hills, Illinois and a distribution warehouse in Gurnee, Illinois. Its three operating segments are: ophthalmic; hospital drugs & injectables; contract services. Ophthalmic Segment: It markets a full line of diagnostic and therapeutic ophthalmic pharmaceutical products. Diagnostic products, primarily used in the office setting, include mydriatics and cycloplegics, anesthetics, topical stains, gonioscopic solutions, angiography dyes and others. Therapeutic products, sold primarily to wholesalers, chain drug stores and other national account customers, include antibiotics, steroids, steroid combinations, glaucoma medications, decongestants/antihistamines and anti-edema medications. Non-pharmaceutical products include various artificial tear solutions, preservative-free lubricating ointments and eyelid cleansers. Hospital Drugs & Injectables Segment - it markets a line of niche hospital drug and injectable pharmaceutical products, including antidotes, anti-infectives, and controlled substances for pain management and anesthesia, and other selected pharmaceutical products. These products are predominately sold to hospitals through the wholesale distribution channel. The Companys customers include physicians, optometrists, hospitals, wholesalers, group purchasing organizations, retail pharmacy chains and other pharmaceutical companies. The Company targets products with limited competition due to difficulty in manufacturing and/or the products market size. Contract Services Segment: It manufactures ophthalmic and injectable pharmaceutical products for third party pharmaceutical customers based on their specifications. The Company is competitors for hospital drugs & injectables segment include both generic and name brand companies such as Hospira, Inc., Teva Pharmaceutical Industries, Pfizer, Sagent Pharmaceuticals, Novartis, Fresenius-Kabi, Daiichi Sankyo, and Hikma. For ophthalmic segment its competitors include, Allergan Pharmaceuticals, Inc., Novartis, Valeant Pharmaceuticals International, Inc., Apotex and Sun Pharmaceuticals, among others.
» More Articles for AKRX

Headlines

Articles On GuruFocus.com
John Paulson Bulks Up Health Care Bet Feb 17 2016 
Analysts Disagree Over Significance of Akorn, Inc’s Financial Errors Apr 28 2015 
Weekly CEO Sells Highlight: Akorn Inc, Under Armour Inc, Anadarko Petroleum Corp, and Graphic Packag Aug 09 2014 
WEEKLY CFO SELLS HIGHLIGHT: AKRX, FIO, OVRL, VRTX Oct 21 2012 
Weekly CFO Sells Highlight: ASGN, COF, AKRX, MCRS, GILD, ROP, PLL Sep 24 2012 
5 Healthcare Picks for 2012 Mar 21 2012 
Weekly CFO Sells Highlight: AN, CATM, AKRX, NNN, FTNT Aug 28 2011 
Akorn Inc. (AKRX) CFO Timothy A Dick buys 3,900 Shares Aug 16 2010 
Akorn Inc. Reports Operating Results (10-Q) May 10 2010 
Akorn Inc. Reports Operating Results (10-Q) Nov 09 2009 

More From Other Websites
Analyzing Akorn’s Strategy to Withstand Generic Industry Challenges Apr 20 2016
Akorn’s Macro-Level Challenges in the Generic Drug Segment Apr 20 2016
New Product Launches Should Boost Akorn’s Revenue in 2016 Apr 15 2016
How Does Akorn Compare to Its Peers in Valuation? Apr 15 2016
Akorn (AKRX) Shares March Higher, Can It Continue? Apr 14 2016
4 Top Ranked Healthcare Stocks that Surged Last Session Apr 07 2016
Akorn, Inc. breached its 50 day moving average in a Bearish Manner : AKRX-US : April 6, 2016 Apr 06 2016
Akorn On Track Mar 28 2016
5 Key Biopharma Movers From Last Week Mar 27 2016
Akorn, Inc. – Value Analysis (NASDAQ:AKRX) : March 24, 2016 Mar 24 2016
Akorn, Inc. breached its 50 day moving average in a Bullish Manner : AKRX-US : March 23, 2016 Mar 23 2016
Edited Transcript of AKRX earnings conference call or presentation 22-Mar-16 2:00pm GMT Mar 22 2016
Five Big Winners in Today’s Trading Session Include Biotech with Promising Drug That Cures... Mar 22 2016
A pharmaceutical company that bungled its 2014 earnings just reported for the first time in a year... Mar 22 2016
Akorn Releases Long-Delayed 2015 Report, 2016 Guidance; Stock Jumps Mar 22 2016
Akorn Back on Track to Restate Results Mar 22 2016
Why Akorn (AKRX) Stock Is Spiking Today Mar 22 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK